| Literature DB >> 35776318 |
Christa E Müller1, Vigneshwaran Namasivayam2.
Abstract
The P2X7 receptor has been proposed as a novel drug target for different types of diseases associated with inflammation, including brain diseases, peripheral inflammation, and cancers. Structurally diverse P2X7 receptor antagonists, mainly negative allosteric modulators (NAMs), have been developed in recent years, and several P2X7 receptor antagonists are currently evaluated in clinical trials. The P2X7 receptor requires high micro- to even millimolar ATP concentrations to be activated. Selective agonists for the P2X7 receptor are not available. Positive allosteric modulators (PAMs) have been described, but PAMs with high potency and selectivity are still lacking. This chapter discusses medicinal chemistry approaches toward the development of P2X7 receptor modulators and presents a selection of recommended tool compounds for studying P2X7 receptors in humans and rodents.Entities:
Keywords: Agonists; Allosteric modulators; Antagonists; Binding site; Depression; Inflammation; Ligands; P2X receptors; Purine receptors; Purinergic signaling; Structure; Tool compounds
Mesh：
Substances：
Year: 2022 PMID： 35776318 DOI： 10.1007/978-1-0716-2384-8_2
Source DB: PubMed Journal: Methods Mol Biol ISSN： 1064-3745